AbCellera Biologics Inc. ABCL Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s investing cash flow?
- AbCellera Biologics Inc. (ABCL) reported investing cash flow of -$25.08M in Q1 2026.
- How has AbCellera Biologics Inc.'s investing cash flow changed year-over-year?
- AbCellera Biologics Inc.'s investing cash flow decreased by 416.1% year-over-year, from $7.94M to -$25.08M.
- What is the long-term trend for AbCellera Biologics Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s investing cash flow has grown at a -28.3% compound annual growth rate (CAGR), from -$332.25M to $87.75M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.